LX4211 tablet: Phase I data
A Phase I trial in 12 patients showed that 2 doses of 150 mg solid oral LX4211 significantly increased total glucagon-like peptide-1 (GLP-1), active GLP-1 and peptide YY (PYY) from baseline (p=0.001, p=0.032 and p=0.004, respectively). Single doses of LX4211 also rapidly and significantly improved post-prandial glucose (PPG) and fasting plasma glucose (FPG).
Patients in the triple-crossover trial received two 150 mg tablets, six 50 mg tablets or one 300 mg liquid dose of LX4211 for 5 days each over a total of 15 days. Data will be presented at the JP Morgan Healthcare Conference in San Francisco on Monday, Jan. 10. Lexicon said it plans to begin a Phase II drug-drug interaction study of the tablet this quarter, with a Phase IIb efficacy study to follow next quarter. ...